ArticleInternational journal of biological sciences2024
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Open access · goldAbstract read
In one paragraph
Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 23 citations in OpenAlex.
- Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.Cancer gene therapy · 2026Article
- Natural Killer Cell Plasticity in Epithelial Ovarian Cancer and Their Therapeutic Implications.Cells · 2026Review
- CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors.Acta neuropathologica communications · 2026Review
- Natural Compounds as Epimodulators in Epithelial Ovarian Cancer.Epigenomes · 2026Review
- Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mesothelin biology and the evolving landscape of targeted immunotherapy.Molecular therapy. Oncology · 2026Review
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- Treatment options in platinum-refractory male germ cell cancers: current standards and future directions.Therapeutic advances in medical oncology · 2026Review
- Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.Frontiers in cell and developmental biology · 2026Review
- Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer communications (London, England) · 2026Review
- The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.Frontiers in immunology · 2026Review
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- Natural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies.International journal of biological sciences · 2026Review
- Advances in adoptive cell therapy for ovarian cancer.Frontiers in immunology · 2026Review
- Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options.Medicina (Kaunas, Lithuania) · 2025Review
- Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy.Journal of ovarian research · 2025Review
- Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.Antibodies (Basel, Switzerland) · 2025Review
- Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment.Annals of medicine · 2025Review
- CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.Biomolecules & therapeutics · 2025Review
- The Metabolic Regulation of the NKG2D-Positive NK and T Cells and Their Role in Disease Progression.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 2 countries.
Junping LiDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Hong HuDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Hui LianDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Shuo YangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Manting LiuDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Jinping HeDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Bihui CaoDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Dongni ChenDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Yuling HuDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Chen ZhiDepartment of Pathology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Yan ShenDepartment of Pathology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Xiaodie YeDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Bingjia HeDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Ming ZhaoMinimally Invasive Interventional Division; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Weijun FanMinimally Invasive Interventional Division; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Linfeng XuDepartment of Interventional Therapy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510260, China.
Rom LeidnerEarle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St., Suite 2N35, Portland, OR 97213, USA.
Qingde WuDepartment of Radiology, Shunde Chinese Medicine Hospital, the Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou, Foshan 528000, China.
Lili YangDepartment of Nutrition; Guangdong Provincial Key Laboratory of Food, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
Zhenfeng ZhangDepartment of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Guangzhou Medical University · CNHubei University of Medicine · CNSecond Affiliated Hospital of Guangzhou Medical University · CNHubei University of Arts and Science · CNSun Yat-sen University · CNXiang Yang No.1 People's Hospital · CNFoshan Hospital of TCM · CNProvidence Portland Medical Center · USSun Yat-sen Memorial Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
ClaudinsOvarian NeoplasmsReceptors, Chimeric AntigenAnimalsApoptosisCD28 AntigensCell Line, TumorFemaleHumansImmunotherapyImmunotherapy, AdoptiveKiller Cells, NaturalMiceNK Cell Lectin-Like Receptor Subfamily KCD28 Antigensclaudin 6ClaudinsNK Cell Lectin-Like Receptor Subfamily KReceptors, Chimeric Antigenchimeric antigen receptorClaudin-6NK cellsovarian cancerPD-1PD-L1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.